The National Screening Unit (NSU) engaged Health Outcomes International Pty Ltd (HOI) to
conduct an independent evaluation of the implementation of digital mammography (DM) at
Breast Screen Waitemata and Northland (BSWN). The overarching purpose of the evaluation was
to assist the NSU to consider options for the managed introduction of DM into the BreastScreen
Aotearoa (BSA) screening programme, and any implications for national policy and quality
standards that this introduction may have.
Women who have symptoms of breast cancer are sometimes referred to BreastScreen
Aotearoa (BSA) by their GP, or self refer to the programme. However, this has a
number of risks, including that the breast cancer may not be detected by a
mammogram and that there will be a delay in the diagnosis of breast cancer.
Dr Madeleine Wall, Clinical Leader, BreastScreen Aotearoa.
This overview of workforce development for BreastScreen Aotearoa (BSA) Medical Radiation Technologists (MRTs) and radiologists is part of the wider workforce initiatives for health professionals within the Ministry of Health.
The purpose of this report is to present information on 2 year interval breast cancers from the BreastScreen Aotearoa (BSA) mammographic screening programme and to compare this with published results from other services.
This systematic review identified and appraised the international evidence for surveillance of women at high risk of breast cancer. The accuracy and health outcome of the following modalities of surveillance were assessed in comparison to normal care: mammography (XRM), ultrasound (US) and magnetic resonance imaging (MRI).
Reviewing the evidence on the benefits, harms and costs of breast cancer screening for women aged 40 to 49 years in New Zealand. Simon Baker, Madeleine Wall, Ashley Bloomfield
The New Zealand Medical Journal. Vol 118 No1221 ISSN1175 8716